Celldex falls after two probable anaphylaxis cases in trials
CLDX•Safety concerns weigh on the stock
Analysts pointed to safety concerns and efficacy over probable anaphylaxis cases reported in trials weighing on shares.
CLDX had gained as much as 45% to $55 in premarket trading following trial results.
The company plans to file for U.S. FDA approval in 2027.
Fourteen of 15 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $56 — data compiled by LSEG.
Including session moves, CLDX stock is up over 21% year to date.
Shares fall after late-stage trial readout
Shares of Celldex Therapeutics CLDX.O were down 12.8% to $33.07, set for their biggest one-day fall in just over a year.
The biotech company said its experimental drug barzolvolimab met the main and all key secondary endpoints in two late-stage studies for chronic spontaneous urticaria.
Chronic spontaneous urticaria is a condition that causes recurring itchy hives and swelling.
